Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2017

Published: Sep, 2017 | Pages: 74 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2017, provides an overview of the Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline landscape.

Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a member of the herpes virus family. It is one of the most common human viruses. EBV spreads most commonly through bodily fluids. EBV can also spread through blood and semen during sexual contact, blood transfusions, and organ transplantations. Symptoms of EBV infections include fatigue, fever, and inflamed throat, swollen lymph nodes in the neck, enlarged spleen, swollen liver and rash.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Epstein-Barr Virus (HHV-4) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 2, 7 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 7, 2, 1 and 2 molecules, respectively.

Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Epstein-Barr Virus (HHV-4) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Epstein-Barr Virus (HHV-4) Infections - Overview
Epstein-Barr Virus (HHV-4) Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Epstein-Barr Virus (HHV-4) Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Epstein-Barr Virus (HHV-4) Infections - Companies Involved in Therapeutics Development
Advenchen Laboratories LLC
Arno Therapeutics Inc
bluebird bio Inc
Cell Medica Ltd
Epiphany Biosciences Inc
Genocea Biosciences Inc
Omeros Corp
TC BioPharm Ltd
Theravectys SA
Viracta Therapeutics Inc
Vironika LLC
ViroStatics srl
Epstein-Barr Virus (HHV-4) Infections - Drug Profiles
apatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AR-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
baltaleucel-T - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for EBV Associated Malignancies - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for EBV Associated PTLD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Systemic Lupus Erythematosus, Epstein-Barr Viral Infections and Multiple Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Viral Infections Post-HSCT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target Calcineurin A for EBV Associated Post Transplant Lymphoproliferative Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target LMP1 for Epstein-Barr Virus Infections and Nasopharyngeal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EBViNT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Epstein-Barr virus (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Epstein-Barr virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GEN-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MVA vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OmnImmune - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prelym - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate ZTA for Epstein-Barr Virus (HHV-4) Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit EBNA1 for Epstein-Barr Virus (EBV) Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target GPR183 for Epstein-Barr Viral Infections and Osteoporosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit EBNA1 for Epstein-Barr Virus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
valomaciclovir stearate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Viralym-M - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Viroprev - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VRx-3996 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Epstein-Barr Virus (HHV-4) Infections - Dormant Projects
Epstein-Barr Virus (HHV-4) Infections - Product Development Milestones
Featured News & Press Releases
Dec 01, 2016: ViraCyte Announces Oral Presentations on Viralym-M Clinical Trial Results at the 58th American Society of Hematology Annual Meeting
Aug 18, 2016: Vironika Secures Phase I SBIR Funding From NIH To Develop Inhibitors For EBV Lytic Reactivation
Jun 02, 2014: Vironika Receives Phase II SBIR Grant From NIH To Continue The Development Of EBV Latency Inhibitors
Mar 25, 2014: University of Birmingham launches trial to fight cancer caused by a common virus
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Epstein-Barr Virus (HHV-4) Infections, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Epstein-Barr Virus (HHV-4) Infections - Pipeline by Advenchen Laboratories LLC, H2 2017
Epstein-Barr Virus (HHV-4) Infections - Pipeline by Arno Therapeutics Inc, H2 2017
Epstein-Barr Virus (HHV-4) Infections - Pipeline by bluebird bio Inc, H2 2017
Epstein-Barr Virus (HHV-4) Infections - Pipeline by Cell Medica Ltd, H2 2017
Epstein-Barr Virus (HHV-4) Infections - Pipeline by Epiphany Biosciences Inc, H2 2017
Epstein-Barr Virus (HHV-4) Infections - Pipeline by Genocea Biosciences Inc, H2 2017
Epstein-Barr Virus (HHV-4) Infections - Pipeline by Omeros Corp, H2 2017
Epstein-Barr Virus (HHV-4) Infections - Pipeline by TC BioPharm Ltd, H2 2017
Epstein-Barr Virus (HHV-4) Infections - Pipeline by Theravectys SA, H2 2017
Epstein-Barr Virus (HHV-4) Infections - Pipeline by Viracta Therapeutics Inc, H2 2017
Epstein-Barr Virus (HHV-4) Infections - Pipeline by Vironika LLC, H2 2017
Epstein-Barr Virus (HHV-4) Infections - Pipeline by ViroStatics srl, H2 2017
Epstein-Barr Virus (HHV-4) Infections - Dormant Projects, H2 2017